中國(guó)醫(yī)藥產(chǎn)業(yè)的國(guó)際競(jìng)爭(zhēng)力研究doc-展示頁
2024-08-01 14:54本頁面
【正文】 Pharmaceutical Administration of China (SPAC). However, the industry is still smallscale, with a scattered geographical layout, duplicated production processes, and outdated manufacturing technology and management structure. The Chinese pharmaceutical industry also has a lower market concentration and weak international trading petitiveness, coupled with a lack of patented pharmaceuticals developed inhouse. However, the industry is still smallscale, with a scattered geographical layout, duplicated production processes, and outdated manufacturing technology and management structure. The Chinese pharmaceutical industry also has a lower market concentration and weak international trading petitiveness, coupled with a lack of patented pharmaceuticals developed inhouse. As China joins the World Trade Organization (WTO), it needs to integrate more pletely into the global economy. The international petition will place an intense pressure on the Chinese pharmaceutical industry and further open the door to a lucrative market for nonChinese panies, especially for pharmaceutical producers and manufacturers. Accession to the WTO binds China by fundamental WTO principles, such as improved transparency and the strengthening of mercial legal procedures. After China39。我國(guó)加入wto后，必須承兌的承諾涉及知識(shí)產(chǎn)權(quán)，關(guān)稅優(yōu)惠，和針對(duì)從事藥品分銷的國(guó)外供應(yīng)商的市場(chǎng)準(zhǔn)入制度。隨著中國(guó)加入世界貿(mào)易組織(WTO)，中國(guó)醫(yī)藥企業(yè)需要更完好地融入全球經(jīng)濟(jì)。然而，中國(guó)的醫(yī)藥行業(yè)依然存在規(guī)模小，布局分散、生產(chǎn)工藝落后的缺點(diǎn)，生產(chǎn)技術(shù)和管理結(jié)構(gòu)過時(shí)的缺點(diǎn)。前言根據(jù)中國(guó)國(guó)家藥品管理中心(SPAC)的統(tǒng)計(jì)，%，然而，中國(guó)的醫(yī)藥行業(yè)依然存在規(guī)模小，布局分散、生產(chǎn)工藝落后的缺點(diǎn)，生產(chǎn)技術(shù)和管理結(jié)構(gòu)過時(shí)的缺點(diǎn)。 制藥工業(yè)的發(fā)展之路 積極發(fā)展中醫(yī)藥產(chǎn)業(yè) 全行業(yè)的發(fā)展該怎樣進(jìn)行 整合——中國(guó)醫(yī)藥企業(yè)的必由之路 確定企業(yè)自身方向最重要 “有準(zhǔn)備”的人在做些什么 我們的醫(yī)藥企業(yè)該怎樣把握新一輪的發(fā)展機(jī)遇 中式成藥 抗菌素（制劑除外） 醫(yī)藥品關(guān)鍵詞研發(fā) 產(chǎn)業(yè)鏈 醫(yī)改 創(chuàng)新 整合 This paper standed in the objective facts levels, with real data as the basis, from the Angle of economics and sociology, systematically analyzed the current Chinese medicine industry development, and Sincerely put forward the heartfelt Suggestions. In the text of the first and second chapter, mainly utilized induce deduction and statistical analysis, this paper introduced the situation of international medical market of China pharmaceutical industry system and make an analysis of operation condition.Using parative analysis respectively, the third chapter made ments of the Chinese chemical pharmacy, biologic pharmacy, TCM plate , and pointed out the problems of pharmaceutical industry chain structure and developmence of productivity.The fourth chapter basically used a trend analysis on the situation and prospect of chinese medicine industry , and propose a feasible and effective strategic development plan.keywordsRamp。第3章 運(yùn)用比較分析法，分別對(duì)中國(guó)化學(xué)制藥、生物制藥、中醫(yī)藥板塊作出評(píng)述，并指出醫(yī)藥行業(yè)整體的產(chǎn)業(yè)鏈結(jié)構(gòu)與研發(fā)生產(chǎn)力的存在問題。n
畢 業(yè) 論 文 論文題目： 中國(guó)醫(yī)藥產(chǎn)業(yè)的 國(guó)際競(jìng)爭(zhēng)力研究 姓 名 張錦明 學(xué) 號(hào) 070401130 專 業(yè) 國(guó)際經(jīng)濟(jì)與貿(mào)易 班 級(jí) 07國(guó)貿(mào)1班 摘要本文站在客觀事實(shí)的層面，以真實(shí)數(shù)據(jù)為依據(jù)，從經(jīng)濟(jì)學(xué)、社會(huì)學(xué)的角度，系統(tǒng)地分析了當(dāng)前中國(guó)醫(yī)藥產(chǎn)業(yè)的發(fā)展?fàn)顩r，并提出懇誠(chéng)的建議。在文中的第一、二章節(jié)中，主要運(yùn)用了歸納演繹法與統(tǒng)計(jì)分析法，介紹了世界醫(yī)藥市場(chǎng)的概況，對(duì)中國(guó)現(xiàn)有醫(yī)藥行業(yè)體系及運(yùn)營(yíng)情況作出分析。第4章 主要運(yùn)用了趨勢(shì)分析法，針對(duì)中國(guó)醫(yī)藥產(chǎn)業(yè)的現(xiàn)狀與前景，提出可行、有效的戰(zhàn)略性發(fā)展方案。D Industry Chain healthcare reform Innovation Consolidation目錄 前言1 國(guó)際醫(yī)藥貿(mào)易概況 世界醫(yī)藥行業(yè)基本情況 2010年 2季度主要產(chǎn)品進(jìn)出口情況 抗菌素制劑 2 中國(guó)醫(yī)藥行業(yè)狀況 行業(yè)規(guī)模與市場(chǎng)分析 行業(yè)規(guī)模 市場(chǎng)分析 行業(yè)財(cái)務(wù)分析與運(yùn)營(yíng)狀況 產(chǎn)銷情況 盈利情況 行業(yè)運(yùn)營(yíng)績(jī)效3 中國(guó)醫(yī)藥產(chǎn)業(yè)國(guó)際競(jìng)爭(zhēng)力水平剖析 三大藥種的產(chǎn)業(yè)競(jìng)爭(zhēng)力分析 生物醫(yī)藥產(chǎn)業(yè)分析 化學(xué)藥產(chǎn)業(yè)分析 中醫(yī)藥產(chǎn)業(yè)分析 中國(guó)醫(yī)藥產(chǎn)業(yè)鏈結(jié)構(gòu)分析 產(chǎn)業(yè)鏈總體概況 主要特征 專注鑄就成功 中國(guó)醫(yī)藥產(chǎn)業(yè)的研發(fā)生產(chǎn)力分析 醫(yī)藥產(chǎn)業(yè)特征 研發(fā)生產(chǎn)力分析4 如何提升我國(guó)醫(yī)藥產(chǎn)業(yè)的國(guó)際競(jìng)爭(zhēng)力 中國(guó)醫(yī)藥產(chǎn)業(yè)未來預(yù)測(cè)未來預(yù)測(cè) 我國(guó)政府對(duì)支持醫(yī)藥產(chǎn)業(yè)發(fā)展的措施 新醫(yī)改推動(dòng)中國(guó)醫(yī)藥市場(chǎng)向前發(fā)展同時(shí)，中國(guó)醫(yī)藥行業(yè)市場(chǎng)集中程度較低及國(guó)際貿(mào)易競(jìng)爭(zhēng)力薄弱，再者就是專利藥品開發(fā)缺乏力度。同時(shí)，中國(guó)醫(yī)藥行業(yè)市場(chǎng)集中程度較低及國(guó)際貿(mào)易競(jìng)爭(zhēng)力薄弱，再者就是專利藥品開發(fā)缺乏力度。加入了世貿(mào)組織，中國(guó)就要遵循WTO的基本原則，比如提高透明度和加強(qiáng)商業(yè)法律程序。所有這些舉措都為國(guó)外醫(yī)藥公司在中國(guó)提供分外有利的商業(yè)機(jī)會(huì)，反過來，國(guó)際競(jìng)爭(zhēng)將給中國(guó)制藥工業(yè)以強(qiáng)烈的壓力。s entry into wto, must abide by mitments include the tightening of rules on intellectual property, tariff concessions, and market access of nonChinese service suppliers e
環(huán)評(píng)公示相關(guān)推薦
鄂ICP備17016276號(hào)-1